デフォルト表紙
市場調査レポート
商品コード
1377973

NanoFluの新興薬剤に関する洞察と市場予測:2032年

NanoFlu Emerging Drug Insight and Market Forecast - 2032

出版日: | 発行: DelveInsight | ページ情報: 英文 30 Pages | 納期: 1~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.46円
NanoFluの新興薬剤に関する洞察と市場予測:2032年
出版日: 2023年11月01日
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 1~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

NanoFluは、NovavaxのSF9昆虫細胞バキュロウイルスシステムで製造される4価の組換えヘマグルチニンタンパク質のナノ粒子インフルエンザワクチンです。NanoFluは、推奨される野生型循環ウイルスのヘマグルチニン配列と同じアミノ酸配列のヘマグルチニンを使用し、ノババックスが特許を有するサポニンベースのMatrix-Mアジュバントを含有しています。ノババックスが特許を有するサポニンベースのMatrix-Mアジュバントは、注射部位への抗原提示細胞の進入を刺激し、局所リンパ節での抗原提示を増強して免疫応答を高めることにより、強力で忍容性の高い効果を実証しています。

Novavaxは、第III相臨床試験で良好な結果を示し、主要な副次的評価項目で統計学的有意性を達成しました。同社は、NanoFluプログラムとNVX-CoV2373の混合ワクチンの臨床試験を開始しました。

当レポートでは、主要7ヶ国におけるNanoFlu市場について調査し、市場の概要とともに、2025年~2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 季節性インフルエンザに対するNanoFluの概要

  • 製品の詳細
  • 臨床開発
    • 臨床研究
    • 臨床試験情報
    • 安全性と有効性
  • その他の開発活動
  • 製品概要

第3章 競合情勢(上市済み治療法)

第4章 競合情勢(後期段階の新興治療法)

第5章 NanoFlu市場評価

  • 季節性インフルエンザに対するNanoFluの市場展望
  • 主要7ヶ国市場分析
    • 主要7ヶ国における季節性インフルエンザに対するNanoFlu市場規模
  • 国別市場分析
    • 米国
    • ドイツ
    • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

図表

List of Tables

  • Table 1: NanoFlu, Clinical Trial Description, 2023
  • Table 2: NanoFlu, General Description
  • Table 3: Competitive Landscape (Marketed Therapies)
  • Table 4: Competitive Landscape (Emerging Therapies)
  • Table 5: NanoFlu Market Size in the 7MM, in USD million (2019-2032)
  • Table 6: NanoFlu Market Size in the US, in USD million (2019-2032)
  • Table 7: NanoFlu Market Size in Germany, in USD million (2019-2032)
  • Table 8: NanoFlu Market Size in France, in USD million (2019-2032)
  • Table 9: NanoFlu Market Size in Italy, in USD million (2019-2032)
  • Table 10: NanoFlu Market Size in Spain, in USD million (2019-2032)
  • Table 11: NanoFlu Market Size in the UK, in USD million (2019-2032)
  • Table 12: NanoFlu Market Size in Japan, in USD million (2019-2032)

List of Figures

  • Figure 1: NanoFlu Market Size in the 7MM, USD million (2019-2032)
  • Figure 2: NanoFlu Market Size in the United States, USD million (2019-2032)
  • Figure 3: NanoFlu Market Size in Germany, USD million (2019-2032)
  • Figure 4: NanoFlu Market Size in France, USD million (2019-2032)
  • Figure 5: NanoFlu Market Size in Italy, USD million (2019-2032)
  • Figure 6: NanoFlu Market Size in Spain, USD million (2019-2032)
  • Figure 7: NanoFlu Market Size in the United Kingdom, USD million (2019-2032)
  • Figure 8: NanoFlu Market Size in Japan, USD million (2019-2032)
目次
Product Code: DIDM1053

“"NanoFlu Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about NanoFlu for seasonal influenza in the seven major markets. A detailed picture of the NanoFlu for seasonal influenza in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NanoFlu for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NanoFlu market forecast analysis for seasonal influenza in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.

Drug Summary:

NanoFlu is a quadrivalent recombinant hemagglutinin protein is a nanoparticle influenza vaccine produced in Novavax' SF9 insect cell baculovirus system. NanoFlu uses hemagglutinin, an amino acid protein sequence that is the same as the recommended wild-type circulating virus hemagglutinin sequences and contains Novavax's patented saponin-based Matrix-M adjuvant. Novavax's patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

Novavax had advanced the NanoFlu program through a Phase III clinical trial, which demonstrated positive topline results and achieved statistical significance in key secondary endpoints. The company has initiated a trial of a combination vaccine consisting of the NanoFlu Program and NVX-CoV2373.

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the NanoFlu description, mechanism of action, dosage and administration, research and development activities in seasonal influenza.
  • Elaborated details on NanoFlu regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the NanoFlu research and development activities in seasonal influenza across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around NanoFlu.
  • The report contains forecasted sales of NanoFlu for seasonal influenza till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for seasonal influenza.
  • The report also features the SWOT analysis with analyst views for NanoFlu in seasonal influenza.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NanoFlu Analytical Perspective by DelveInsight

  • In-depth NanoFlu Market Assessment

This report provides a detailed market assessment of NanoFlu for seasonal influenza in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

  • NanoFlu Clinical Assessment

The report provides the clinical trials information of NanoFlu for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for seasonal influenza is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NanoFlu dominance.
  • Other emerging products for seasonal influenza are expected to give tough market competition to NanoFlu and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NanoFlu in seasonal influenza.
  • Our in-depth analysis of the forecasted sales data of NanoFlu from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NanoFlu in seasonal influenza.

Key Questions

  • What is the product type, route of administration and mechanism of action of NanoFlu?
  • What is the clinical trial status of the study related to NanoFlu in seasonal influenza and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NanoFlu development?
  • What are the key designations that have been granted to NanoFlu for seasonal influenza?
  • What is the forecasted market scenario of NanoFlu for seasonal influenza?
  • What are the forecasted sales of NanoFlu in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how are these giving competition to NanoFlu for seasonal influenza?
  • Which are the late-stage emerging therapies under development for the treatment of seasonal influenza?

Table of Contents

1. Report Introduction

2. NanoFlu Overview in seasonal influenza

  • 2.1. Product Detail
  • 2.2. Clinical Development
    • 2.2.1. Clinical studies
    • 2.2.2. Clinical trials information
    • 2.2.3. Safety and efficacy
  • 2.3. Other Developmental Activities
  • 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. NanoFlu Market Assessment

  • 5.1. Market Outlook of NanoFlu in seasonal influenza
  • 5.2. 7MM Analysis
    • 5.2.1. Market Size of NanoFlu in the 7MM for seasonal influenza
  • 5.3. Country-wise Market Analysis
    • 5.3.1. Market Size of NanoFlu in the United States for seasonal influenza
    • 5.3.2. Market Size of NanoFlu in Germany for seasonal influenza
    • 5.3.3. Market Size of NanoFlu in France for seasonal influenza
    • 5.3.4. Market Size of NanoFlu in Italy for seasonal influenza
    • 5.3.5. Market Size of NanoFlu in Spain for seasonal influenza
    • 5.3.6. Market Size of NanoFlu in the United Kingdom for seasonal influenza
    • 5.3.7. Market Size of NanoFlu in Japan for seasonal influenza

6. SWOT Analysis

7. Analysts' Views

8. Appendix

  • 8.1. Bibliography
  • 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options